Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug669 | COVID-19 swap test PCR Wiki | 0.25 |
| drug2846 | Rehabilitation exercise protocol Wiki | 0.25 |
| drug45 | 3D Wiki | 0.25 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2914 | Rivaroxaban 2.5 Mg Oral Tablet Wiki | 0.25 |
| drug2915 | Rivaroxaban placebo tablets Wiki | 0.25 |
| drug1587 | ID NOW vs. Accula Wiki | 0.25 |
| drug3883 | exposure Wiki | 0.25 |
| drug2048 | MindRhythm Harmony Wiki | 0.25 |
| drug3163 | Sofosbuvir Wiki | 0.25 |
| drug1420 | Group Lifestyle Balance Wiki | 0.25 |
| drug2919 | Robotic therapy Wiki | 0.25 |
| drug3102 | Serology Test Wiki | 0.25 |
| drug3951 | mHealth Assessments Wiki | 0.25 |
| drug27 | 1D Wiki | 0.25 |
| drug1986 | Mechanical Trombectomy Wiki | 0.25 |
| drug2284 | Observation Wiki | 0.18 |
| drug783 | Chloroquine or hydroxychloroquine Wiki | 0.18 |
| drug981 | Daclatasvir Wiki | 0.18 |
| drug527 | Blood sampling Wiki | 0.14 |
| drug464 | Best Practice Wiki | 0.11 |
| drug3603 | Usual Care Wiki | 0.08 |
| drug3485 | Tocilizumab Wiki | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013226 | Status Epilepticus NIH | 0.25 |
| D002543 | Cerebral Hemorrhage NIH | 0.25 |
| D013345 | Subarachnoid Hemorrhage NIH | 0.25 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D016757 | Death, Sudden, Cardiac NIH | 0.25 |
| D017180 | Tachycardia, Ventricular NIH | 0.25 |
| D004827 | Epilepsy NIH | 0.25 |
| D003072 | Cognition Disorders NIH | 0.18 |
| D013610 | Tachycardia NIH | 0.18 |
| D007238 | Infarction NIH | 0.16 |
| D012640 | Seizures NIH | 0.14 |
| D009422 | Nervous System Diseases NIH | 0.14 |
| D003643 | Death, NIH | 0.13 |
| D006470 | Hemorrhage NIH | 0.13 |
| D009203 | Myocardial Ischemia NIH | 0.12 |
| D007511 | Ischemia NIH | 0.10 |
| D010300 | Parkinsonian NIH | 0.09 |
| D007676 | Kidney Failure, Chronic NIH | 0.09 |
| D003324 | Coronary Artery Disease NIH | 0.09 |
| D000070642 | Brain Injuries, Traumatic NIH | 0.09 |
| D001930 | Brain Injuries, NIH | 0.08 |
| D029424 | Pulmonary Disease, Chronic Obstructive NIH | 0.07 |
| D060825 | Cognitive Dysfunction NIH | 0.07 |
| D008173 | Lung Diseases, Obstructive NIH | 0.07 |
| D003866 | Depressive Disorder NIH | 0.05 |
| D014947 | Wounds and Injuries NIH | 0.05 |
| D009369 | Neoplasms, NIH | 0.05 |
| D004194 | Disease NIH | 0.04 |
| D001008 | Anxiety Disorders NIH | 0.04 |
| D003863 | Depression, NIH | 0.03 |
| D007239 | Infection NIH | 0.01 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.01 |
| D018352 | Coronavirus Infections NIH | 0.01 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001297 | Stroke HPO | 0.90 |
| HP:0002133 | Status epilepticus HPO | 0.25 |
| HP:0002138 | Subarachnoid hemorrhage HPO | 0.25 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001342 | Cerebral hemorrhage HPO | 0.25 |
| HP:0004756 | Ventricular tachycardia HPO | 0.25 |
| HP:0001645 | Sudden cardiac death HPO | 0.25 |
| HP:0001649 | Tachycardia HPO | 0.18 |
| HP:0001250 | Seizure HPO | 0.14 |
| HP:0001677 | Coronary artery atherosclerosis HPO | 0.10 |
| HP:0006510 | Chronic pulmonary obstruction HPO | 0.08 |
| HP:0006536 | Pulmonary obstruction HPO | 0.08 |
| HP:0001268 | Mental deterioration HPO | 0.08 |
| HP:0001658 | Myocardial infarction HPO | 0.07 |
| HP:0002664 | Neoplasm HPO | 0.05 |
Navigate: Correlations HPO
There are 16 clinical trials
The purpose of this RCT is to examine the efficacy of the Group Lifestyle Balance (GLB) program adapted for people with stroke (CVA) on primary (weight) and secondary outcomes at 3, 6, 12 months from enrollment into the program.
Description: Will be obtained using the same scale over the study period that is accessible to people with and without a mobility device (e.g., walker; wheelchair).
Measure: Change in weight Time: Baseline, 3, 6, 12 monthsDescription: Accelerometers will be worn by participants for two weeks around each study visit to objectively track physical activity participation (amount and intensity). Participants will be given the Actigraph accelerometer at the beginning of the study and will be provided with verbal and written instructions.
Measure: Physical Activity Time: Baseline, 3, 6, 12 monthsDescription: Arm circumference measured at mid-upper arm following ACSM guidelines. A total of three measurements will be taken and an average of the three will be used. Measurements will be taken in centimeters.
Measure: Arm Circumference Time: Baseline, 3, 6, 12 monthsDescription: Using an automatic cuff (average of three readings, patient seated) diastolic and systolic scores will be recorded
Measure: Blood Pressure Time: Baseline, 3, 6, 12 monthsDescription: Fasting venous sample will be obtained. Coordinators are trained phlebotomists.
Measure: Cholesterol Time: Baseline, 3, 6, 12 monthsDescription: The Framingham Heart Study diabetes risk score will be calculated using predictors including age, gender, fasting glucose, BMI, HDL cholesterol and triglyceride levels, blood pressure, and parental history. Risk score calculator and regression model are free and used in GLB weight-loss trials. Risk score calculator and regression model are free and used in GLB weight-loss studies. Each risk predictor is assigned points ranging from 2-10. Risk factors are combined and a total score is calculated, with higher scores designating greater 8-year risk.The age range for this score is 45 years to 64 years, and therefore only individuals within this age will have calculated scores. Furthermore, the minimum cut-off score is 3.
Measure: Risk of Diabetes Time: Baseline, 3, 6, 12 monthsDescription: Assesses walking speed in (m/s) which is correlated to mobility in the community, capacity to perform ADLs, risk of falls, re-hospitalization, and risk of cognitive decline.
Measure: 10 Meter Walk Test (10MWT) Time: Baseline, 3, 6, 12 monthsDescription: Assesses distance walked over 6 minutes as a sub-maximal test of aerobic capacity. Endurance is essential to participate in community-based activities.
Measure: 6 Minute Walk Test (6MWT) Time: Baseline, 3, 6, 12 monthsDescription: The Multidimensional Scale of Perceived Social Support (MSPSS) is comprised of 12 questions with a 4-item subscale. The MSPSS is designed to assess perception of social support from friends, family, and significant others
Measure: Perceived Social Support Time: Baseline and 12 monthsDescription: Measure includes 28 items that assess health practices among people with disabilities and yields a total Health Practices score plus 4 subscales scores regarding Exercise, Nutrition, Health Practices, and Psychological Well Being. Items are rated on a 5-point scale from 0 'not at all' to 4 'completely.' Scores range from 0-28 with higher scores indicating higher exercise self-efficacy.
Measure: Self-reported activities of health using the Self-Rated Abilities for Health Practice scale Time: Baseline and 12 monthsDescription: Walk Score® is publicly available and measures the walkability of any address using a patented system. For each address, Walk Score ® analyzes hundreds of walking routes to nearby amenities and awards points based on distance to each amenity. Walk Score® also measures pedestrian friendliness by analyzing population density and road metrics such a block length and intersection density. Scores are given on a scale of 0 to 100.
Measure: Neighborhood walkability using Walk Score® Time: BaselineDescription: MedGem® is an FDA cleared and validated indirect calorimetry device. It is handheld and measures oxygen consumption (V02) to determine resting metabolic rate (RMR).
Measure: Resting Metabolic Rate Time: BaselineDescription: The BRFSS is a state-based system of health surveys that collects information on health risk behaviors, preventative health practices, and health care access primarily related to chronic disease and injury. The GLB-TBI uses the two subscales of Healthy Eating and Physical Activity from the 2017 version of the BRFSS. It consists of 14 items.
Measure: Behavioral Risk Factor Surveillance Time: Baseline, 3, 6, 12 monthsDescription: Quality of life will be assess using the stroke impact scale (SIS), which assesses 8 dimensions of health-related QOL specific to people post CVA including subscales (using a 5pt Likert scale) assessing strength, memory and thinking, emotion, communication, activities of daily living, mobility, hand function, and participation/role function
Measure: Participant quality of ife Time: Baseline, 6, 12 monthsDescription: This inventory consists of 40 life events and asks the participant to recall if any of the events happened within the previous year (e.g., death of spouse; personal illness; change in sleep). Endorsement of these events are totaled and higher scores indicate a greater amount of stressful life events. Point values for the Holmes and Rahe Stress Inventory were weighted and summed for each individual based on scoring instructions. Individuals who scored 150 points or less were categorized as low susceptibility to a health breakdown in the next two years, 151-300 points were 50% chance of health breakdown, and 301 points or more were 80% chance of health breakdown.
Measure: Stressful Life Events using the Holmes and Rahe Stress Inventory Time: Baseline and 12 monthsDescription: The MOCA is a brief, 8-section assessment of various cognitive domains including executive function, memory, language, attention, concentration, orientation, and working memory in neurologic populations.Each item on the MOCA is allocated a set of points adding up to 30.
Measure: Executive Function and Cognition using the Montreal Cognitive Assessment Time: Baseline, 3, and 12 monthsDescription: The self-reported habit index (SRHI) measures the self-reported perceptions of habit strength for an identified behavior. It consists of 12 items for each selected behavior and uses a 7-point Likert scale from "completely disagree" to "completely agree." Higher totals represent greater perception of habit strength. The SRHI showed high reliability across four studies with alphas of .89, .92, .89, .94, .95, .94, and .85.
Measure: Habit Formation Time: Baseline, 3, and 12 monthsDescription: The Modified Rankin Scale (MRS) measures the degree of disability or dependence for daily activities of people who have had a stroke. The MRS is an ordinal scale with six categories ranging from zero (no symptoms) to five (complete physical dependence). A score of six signifies death.
Measure: Stroke Severity Time: BaselineDescription: The Pain Interference-Short Form is taken from the Patient-Reported Outcomes Measurement Information System (PROMIS). This measure is used to assess adult self-reported consequences of pain and pain consequences (e.g. interference in social, cognitive, emotional, physical and recreational activities). This measure consists of four questions with five response option ranging from one to five. The sum of all responses creates a total raw score. This measure is normed to the US general population.
Measure: Pain Interference Time: Baseline, 3, 6, and 12 monthsDescription: The Sleep Disturbance-Short Form 4a is taken from the Patient-Reported Outcomes Measurement Information System (PROMIS) and used to assess adult sleep disturbance profiles. This measure has four questions, each with five response options ranging in value from one to five. The sum of each response creates a total raw score. The measure is normed to the US general population.
Measure: Sleep Disturbance Time: Baseline, 3, 6, 12 monthsDescription: Waist circumference will be measured at the umbilicus following ACSM guidelines. A total of three measurements will be taken and an average of the three will be the final measurement used. Measurements will be scored in centimeters.
Measure: Waist Circumference Time: Baseline, 3, 6, and 12 monthsDescription: Fasting venous sample will be obtained for hemoglobin a1c to assess average blood sugar level over the past 2-3 months. Coordinators are trained phlebotomists.
Measure: HbA1c Time: Baseline, 3, 6, and 12 monthsDescription: Fasting venous sample will be obtained. Coordinators are trained phlebotomists.
Measure: Triglycerides Time: Baseline, 3, 6, 12 monthsDescription: Fasting venous sample will be obtained. Coordinators are trained phlebotomists.
Measure: Blood Glucose Time: Baseline, 3, 6, 12 monthsDescription: Isrin, Angiogenic factors (VEGF), Total Homocysteine, Lipoprotein-associated phospholipase A2 (Lp-PLA2), ICF-1, Brain derived neurotrophic factor (BDNF), and Tau proteins (total and phosphorylated) will be drawn to assess relationships with outcome variables.
Measure: Biomarker Analysis Time: Baseline, 3, and 6 monthsDescription: A modified version of Prochaska and DiClemente's Stages of Change model will be administered to measure readiness for behavior change. The measure consists of two behaviors (eating and exercise) with five questions each related to a stage of change (precontemplation, contemplation, preparation, action, maintenance).
Measure: Stages of Change Time: Baseline, 3, 6, and 12 monthsDescription: The metabolic score calculator will be used at all time points to determine the risk for metabolic syndrome. The following variables will be used to determine metabolic risk using the free metabolic risk calculator: gender, race and ethnicity, systolic blood pressure, fasting glucose, triglycerides, high-density lipoprotein (HDL), weight, height, and waist circumference. Scores are calculated are standardized to the general population.
Measure: Metabolic Score Calculator (MetS) Time: Baseline, 3, 6, and 12 monthsDescription: This self-report survey was developed by the National Institute of Mental Health. The full survey consists of 64 questions with an open-ended section at the end to elicit concerns and feedback related to the effects of COVID-19. For this current study, however, only sections on Exposure Status (10 items), Life Changes (15 items), and Emotions/Worries (7 items), and the open-ended question will be asked. Questions are asked "over the past two weeks."
Measure: CRISIS (CoRonavIruS Health Impact Survey) V0.3 Adult Baseline Form Time: Up to 12 monthsDescription: The Social Isolation Short-Form 4a is taken from the Patient-Reported Outcomes Measurement Information System (PROMIS). This form assesses the perceptions of being "avoided, excluded, detached, disconnected from, or unknown by, others. There is no timeframe for the form. The measure is normed to the US population.
Measure: PROMIS Social Isolation Short Form 4a Time: Up to 12 monthsDescription: To assess media exposure and fear of media exposure during COVID-19 we have added 6 questions. These are asked "over the past two weeks." These questions address time spent watching the television, listening to radio, reading the newspaper, and searching the internet and social media. In addition, a 6th question related to fear is asked using a 5-point Likert scale.
Measure: Media Questionnaire Time: Up to 12 monthsDespite the functional importance, fingertip forces are rarely explicitly addressed with feedback in therapy. This gap in treatment is due to a lack of tools to provide explicit feedback on patients' volitional finger force generation. To address this unmet need, the investigators developed a novel tool for practice of volitional three-dimensional (3D) force generation with explicit feedback. The objective of this project is to determine if 3D finger force training is an effective tool in restoring hand function post stroke.
Description: a clinical assessment for upper extremity function
Measure: Action Research Arm Test (ARAT) Time: 3rd baseline to within 1 week post interventionDescription: a clinical assessment for upper extremity function.
Measure: Box and Block Test Time: 3rd baseline to within 1 week post interventionDescription: Angular deviation of the grip force vector from the target direction
Measure: Force Direction Time: 3rd baseline to within 1 week post interventionDescription: a clinical assessment for upper extremity function
Measure: Action Research Arm Test Time: 3rd baseline to 1 month post interventionDescription: a clinical assessment for upper extremity function.
Measure: Box and Block Test Time: 3rd baseline to 1 month post interventionApproximately 17% of all patients with stroke are classified as having ESUS, which is associated with a considerable rate of stroke recurrence 4-5 % per year. Despite recent scientific advances in acute ischemic stroke treatment in recent decades,consensus treatment of all guidelines is still ASA
Description: Number of stroke events during 1 year of study
Measure: Rate of stroke recurrence Time: Rate of stroke recurrence during one year fallow upDescription: Rate of major bleeding according to criteria of the International Society of Thrombosis and Hemostasis
Measure: Rate of major bleeding Time: During 1 year of studyDescription: Number of stroke or systemic embolisms recurrence during 1 year of study
Measure: Rate of stroke or systemic embolisms Time: During 1 year of studyDescription: Number of all cause mortality during study
Measure: Mortality rate Time: During 1year of studyDescription: Rate of non-major bleeding according to criteria of the International Society of Thrombosis and Hemostasis
Measure: Rate of non-major bleeding Time: During 1year of studyDescription: Rate of ICH during study
Measure: Rate of intracranial bleeding Time: During 1year of studyDescription: Rate of fatal bleeding in any site
Measure: Rate of fatal bleeding Time: During 1 year of studyThis phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS is a potentially serious disorder caused by the release of an excessive amount of substance that is made by cells of the immune system (cytokines) as a response to viral infection. Tocilizumab is used to decrease the body's immune response. Adding tocilizumab to standard of care may work better in treating CRS in patients with SARS-CoV-2 infection compared to standard of care alone.
Description: The 7-day length of invasive MV for each arm will be estimated with 95% confidence intervals (CIs) using the exact binomial distribution. Their difference by the arms will be tested by Cochran-Mantel-Haenszel (CMH) test stratified by the age group and Sequential Organ Failure Assessment (SOFA) score at significance level of 0.05.
Measure: 7-day length of invasive mechanical ventilation (MV) Time: Up to 7 daysDescription: Defined as death within 30-day after randomization. The 30-day mortality rate for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: 30-day mortality rate Time: Up to 30-day after randomizationDescription: The rate of ICU transfer for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: Rate of intensive care (ICU) transfer Time: Up to 2 yearsDescription: The rate of invasive mechanical ventilation for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: Rate of invasive mechanical ventilation Time: Up to 2 yearsDescription: The rate of tracheostomy for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: Rate of tracheostomy Time: Up to 2 yearsDescription: Will first be described by median and inter-quartile, and then compared between two arms by Wilcoxon Sum-Rank test
Measure: Length of ICU stay Time: Up to 2 yearsThe current COVID19 pandemic has afflicted almost the whole globe. The stress related to the pandemic, not the direct virus-related injury, can be potentially associated with acute cardiovascular events due to a large list of physical and psychosocial stresses. This study is a cross sectional study that will enroll patients evaluated during the COVID19 pandemic period for acute cardiovascular events.
Description: Acute myocardial infarction as diagnosed by ST segment elevation or depression or inverted T wave on 12-lead EKG and elevated levels of cardiac troponins above the 99% of the normal values. A. Acute MI (STEMI and NSTEMI). B. Aborted on non-aborted sudden cardiac death not attributed to a known etiology. C. Sustained or non-sustained ventricular tachy-arrhythmia not attributed to a known etiology. D. ICD shocks. 3. Absence of suspected or confirmed infection with the COVID19 virus. 4. Definite physical or psycho-social stressful trigger appearing in relation to the COVID-19 situation (lock down stress, financial stress, anger, depression, fear, sorrow, death of a significant person, eating binges, smoking binges, physical stress [carrying walking for shopping and carrying excess weights] ..etc) as judged by a unanimous agreement of three investigators in the steering committee.
Measure: Acute cardiovascular event triggered by COVID-19 stress Time: 4 monthsDescription: Typical ventricular tachycardia on 12-lead EKG or EKG monitor.
Measure: Ventricular tachycardia Time: 4 monthsDescription: acute neurological symptoms of hemiparesis or dysrthria due to brain ischemia proven by computerized tomography or magnatic resonance
Measure: acute stroke Time: 4 monthsDescription: Finding an episode of ventricular tachycardia on interrogation of ICD tracing
Measure: Implantable cardioverter defibrillator (ICD) shock Time: 4 monthsThe Covid-19 pandemic is a pandemic of an emerging infectious disease, coronavirus 2019 (Covid-19), caused by the coronavirus SARS-CoV-2. It appears in November 2019 in the city of Wuhan, China, and spreads worldwide from February 2020. The first cases of infection in France were confirmed on 24 January 2020. As of April 14, 103,573 cases of infection were confirmed, 32,292 hospitalized cases, including 6,730 in intensive care, with 15,729 deaths recorded1. The most affected regions are Ile de France and the Grand Est (in particular the Haut-Rhin department). Containment of the entire French population was introduced on 17 March, with the aim of reducing the spread of the virus and relieving the burden on the health system, particularly the intensive care units. This unprecedented health crisis, as well as the social containment measures in themselves, has repercussions on other acute medical pthologies, not directly related to the viral infection. It appears that the number of patients treated for acute stroke has suddenly declined since the beginning of the epidemic. However, it is not clear whether it is the incidence of stroke that has declined or simply the proportion of patients presenting within the time frame that allows for treatment in the acute phase (by thrombolysis or thrombectomy).
COVID-19 has a big impact on individuals and society as a whole. Especially persons with (multiple) comorbidities such as stroke are affected. The impact of COVID-19 on stroke rehabilitation delivery and stroke patients' functioning is unclear.
Description: Nature of rehabilitation therapy, and number and duration of rehabilitation therapy sessions
Measure: Rehabilitation data Time: 3 month after start lockdownDescription: Patient-reported upper limb use in daily life
Measure: Motor Activity Log - 14 Item Version Time: 3 month after start lockdownDescription: Patient-reported engagement in physical activity in daily life
Measure: International Physical Activity Questionnaire Time: 3 month after start lockdownDescription: Patient-self-assessment comprising the following categories: 1) physical function, 2) anxiety, 3) depression, 4) fatigue, 5) sleep disturbance, 6) ability to participate in social roles and activities, 7) pain interference and 8) pain intensity
Measure: Patient-Reported Outcomes Measurement Information System - 29 Version Time: 3 month after start lockdownDescription: Patient-reported global rating of physical activity engagement and upper limb use in daily life
Measure: Global Rating of Perceived Changes (physical activity engagement and upper limb use) Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Self-reported questionnaire regarding severity of fatigue and its influence on the performance of daily life activities
Measure: Fatigue Severity Scale Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Depression and anxiety
Measure: Hospital Anxiety and Depression Scale Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Assesses cognitive functions
Measure: Montreal Cognitive Assessment Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Classification regarding the ability to walk independently, with or without a walking aid and takes the type of walking surface into account
Measure: Functional Ambulation Categories Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Gait speed and cadence
Measure: Ten-Meter Walk Test Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Measures the ability of patients to make postural adjustments (e.g, move in bed), transfer (e.g. be-tween bed to chair), walk, and use stairs
Measure: Rivermead Mobility Index Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Self-reported measure in which patients rate how confident they are in maintaining balance when performing 16 daily life tasks
Measure: Activities-specific Balance Confidence Scale Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Upper and lower limb motor function
Measure: Fugl-Meyer Motor Assessment Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Upper limb capacity
Measure: Action Research Arm Test Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Global disability
Measure: modified Rankin Scale Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Neurological impairments
Measure: National Institutes of Health Stroke Scale Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdownDescription: Nature of rehabilitation therapy, and number and duration of rehabilitation therapy sessions
Measure: Rehabilitation data Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 6 months after lockdownDescription: Patient-reported upper limb use in daily life
Measure: Motor Activity Log - 14 Item Version Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 6 months after lockdownDescription: Patient-reported engagement in physical activity in daily life
Measure: International Physical Activity Questionnaire Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 6 months after lockdownDescription: Patient-self-assessment comprising the following categories: 1) physical function, 2) anxiety, 3) depression, 4) fatigue, 5) sleep disturbance, 6) ability to participate in social roles and activities, 7) pain interference and 8) pain intensity
Measure: Patient-Reported Outcomes Measurement Information System - 29 Version Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 6 months after lockdownThe purpose is to investigate the COVID-19 prevalence, associated morbidity and long-term cognitive deficits in consecutive patients presenting with acute neurological symptoms
Description: To investigate the prevalence of COVID-19 infections in consecutive patients with acute onset of neurological symptoms (with or without prior neurological disease)
Measure: Prevalence of COVID-19 infection in consecutive patients with neurological symptoms Time: 6 monthsDescription: Three months cognitive function (Montreal Cognitive Assessment) of COVID-19 positive patients compared to COVID-19 negative patients
Measure: Three months cognitive function of COVID-19 positive patients Time: 3 monthsDescription: Characterization of the neurological symptoms in neurological COVID-19 positive patients (exploratory endpoint)
Measure: Clinical presentation of neurological symptoms in COVID-19 positive patients Time: 6 monthsDescription: Prevalence of pre-symptomatic and asymptomatic COVID-19pos in acutely admitted patients with a primary complaint of neurological symptoms.
Measure: Prevalence of pre- and asymptomatic COVID-19 positive patients in acutely admitted neurological patients Time: 6 monthsDescription: Prevalence of anosmia in COVID-19pos patients compared to COVID-19neg patients
Measure: Anosmia in COVID-19 positive patients Time: 6 monthsDescription: Neuro-specific and inflammatory blood- and cerebrospinal fluid markers in COVID-19 positive patients compared to COVID-19 negative matched controls
Measure: Exploratory analysis on neuro-specific and inflammatory blood and cerebrospinal fluid markers of COVID-19 infection Time: 24 monthsDescription: Functional and immunologic plasma assays will be employed to analyze proteins and pathways in coagulation and fibrinolysis
Measure: Exploratory analysis of the coagulation profile of COVID-19 positive patients compared to COVID-19neg patients Time: 24 monthsThe COVID-19 outbreak requires a rapid re-shaping of the entire organization of the rehabilitation services. This includes the design and planning of appropriate rehabilitation settings, intervention and logistics for organizing space for patients. The aims of this study are: (a) to evaluate the feasibility of the bedside use of a novel rehabilitation device for upper limb in patients with stroke; (b) to evaluate the motor and cognitive outcomes of the treatment; (c) to validate the instrumental outcomes provided by the device.
Description: It is a tool for measuring the usability
Measure: System Usability Scale (SUS) Time: After 30 rehabilitation sessionsDescription: It is a tool for measuring the acceptability.
Measure: Technology Acceptance Model (TAM) Time: After 30 rehabilitation sessionsDescription: It is a tool for measuring the satisfaction.
Measure: Likert Scale Time: After 30 rehabilitation sessionsDescription: The Fugl-Meyer Assessment is a stroke-specific, performance-based impairment index. It is designed to assess motor functioning, sensation and joint functioning in patients with post-stroke hemiplegia. It is applied clinically and in research to determine disease severity, describe motor recovery, and to plan and assess treatment.
Measure: Fugl-Meyer Assessment for upper extremity (FMA-UE) Time: At baseline; after 30 rehabilitation sessionsDescription: It is a clinical instrument for characterizing the strength of the paretic upper extremity following stroke.
Measure: Motricity Index for the upper extremity (MI-UE) Time: At baseline; after 30 rehabilitation sessionsDescription: It is a clinical instrument for characterizing upper limb spasticity. Shoulder, elbow and wrist spasticity will be assessed.
Measure: Modified Ashworth Scale (MAS) Time: At baseline; after 30 session rehabilitation sessionsDescription: It is a unidimensional measure of pain intensity in adults.
Measure: Numeric Pain Rating Scale (NPRS) Time: At baseline; after 30 rehabilitation sessionsDescription: It is a measure of independence in activities of daily living.
Measure: Modified Barthel Index (mBI) Time: At baseline; after 30 rehabilitation sessionsDescription: It is a widely used screening assessment for detecting cognitive impairment.
Measure: Montreal Cognitive Assessment (MoCA) Time: At baseline; after 30 rehabilitation sessionsDescription: The kinematics of the end-effector of the robot will be acquired during point-to-point tasks.
Measure: Kinematic parameters Time: At baseline (twice, one day apart); after 10 rehabilitation sessions; after 20 rehabilitation sessions; after 30 rehabilitation sessionsAbout 5% of COVID-19 patients may present symptoms related to acute ischemic stroke (AIS). Treatment-management and outcomes related to mechanical thrombectomy (MT) for COVID-19 infected patients harboring large vessel occlusion is largely unknown. This multicentric study aims to investigate morbidity, mortality and neurological outcomes after MT performed in patients with COVID-19 infection.
Description: Intrahospital mortality after MT for COVID-19 infected patients harboring large vessel occlusion
Measure: Intrahospital mortality Time: 1dayDescription: short-term morbidity after MT for COVID-19 infected patients harboring large vessel occlusion
Measure: short-term morbidity Time: 1 dayDescription: Angiographic success after MT for COVID-19 infected patients harboring large vessel occlusion
Measure: Angiographic success Time: 1 dayPrehospital providers encounter patients with suspected stroke frequently. Stroke and COVID-19 are related potentially putting these healthcare workers at risk of COVID-19 infection. In addition, prehospital providers need tools to help triage large vessel stroke patients to comprehensive stroke centers.
Description: Proportion of head pulse studies deemed of high quality for further analysis
Measure: Quality head pulse recordings Time: Through Study Completion, an average 6 monthsBackground: Coronavirus (CoViD-19) positive stroke survivors (SSv) with comorbidities faces possibility for mortality. Study reports success of physiotherapy in CoViD-19 positive SSv with multiple comorbidities. Methods: This clinical controlled study involve a minimum of 30 SSv and 30 age and sex-matched non-stroke individuals with multiple comorbidities with CoViD-19 status confirmed using Real-Time Quantitative-Polymerase Chain Reaction. The Cycle Threshold (CT) and nucleic acid content in the test sample (NA) will be recorded from the virology test results. Their exercise endurance, exercise capacities and quality of life will be assessed using 3-minutes' walk test and 3-meters test and Stroke Specific Quality of Life Questionnaire. Measurements will be taken at every three days intervals from admission to discharge from hospital-isolation. They will receive their normal treatments for CoViD-19 in addition to daily Physiotherapy for the SSv delivered through E-Platform. the Zoom and the WhatsApp video platforms will be used for the interactions between the physiotherapists and the participants. A pre-tested exercise protocol for stroke patients developed by the Stroke and Nervous System Disorders research group of the University of Lagos, Nigeria will be used for the E-exercises. The exercise package will be loaded into the phones of the participants at hospital admission. The Physiotherapists will lead in the exercises through video interaction will the participants watches the video programme. Their risks for respiratory complications (RC), ventilation (RV) and death (RD) will be analysed. Data will be analysed using independent t-test, Analysis of Co-Variance, and multivariate retrogression, survival analyses, Friedman Analysis of Variance and MannWithney U test (95% Confident Interval). Anticipated Outcomes: It is anticipated that the outcome of this study will provide evidence for inclusion of Physiotherapy in the acute management of individuals tested positive for CoViD-19 most important for the stroke survivors tested positive for CoViD-19 at acute stage to reduce the odds of developing complications expedite discharge and reduce odd of death.
Description: The CT value of a reaction is defined as the cycle number when the fluorescence of a PCR product can be detected above the background signal. The CT value is associated with the amount of PCR product in the reaction. The lower the CT value, the more PCR product that is present. It does not have unit of measurement
Measure: Cycle Threshold (CT) values as recorded from the series of the qRT-PCR Time: From date of admission until the date of discharge from the isolation ward or date of death, whichever came first, assessed up to 18 months. Length of hospital stay before discharge/death will be documentedDescription: This is the inverse of the Cycle Threshold. It does not have unit of measurement.
Measure: Nucleic acid values as calculated from the Cycle Threshold recorded from the series of the qRT-PCR Time: From date of admission until the date of discharge from the isolation ward or date of death, whichever came first, assessed up to 18 months. Length of hospital stay before discharge/death will be documentedDescription: Perceived life experience by the participants in relation to the present situation. It does not have unit of measurement.
Measure: Quality of Life perception Time: From date of admission until the date of discharge from the isolation ward or date of death, whichever came first, assessed up to 18 months. Length of hospital stay before discharge/death will be documentedDescription: The maximum amount of physical exertion that a patient can sustain. It will be tested using the 3-metre walk test. This is the time taken to complete a 3-metre distance. The unit of measurement is in seconds
Measure: Exercise capacity Time: From date of admission until the date of discharge from the isolation ward or date of death, whichever came first, assessed up to 18 months. Length of hospital stay before discharge/death will be documentedDescription: The maximum length a patient can sustain an exercise procedure, It will be tested using the 3-minutes' walk test This is the distance covered within a 3-minute walk. The unit of measurement is in metres
Measure: Exercise endurance Time: From date of admission until the date of discharge from the isolation ward or date of death, whichever came first, assessed up to 18 months. Length of hospital stay before discharge/death will be documentedA prospective cohort minimal risk study to determine the impact of the COVID-19 crisis on outcomes of neurologically injured ICU patients.
Description: Care treatment such as ventilator use, intubation, and/or tracheostomy
Measure: Limitations of patient care- Frequency of care not being provided Time: During In-hospital course, up to 1 monthThe study aimed at describing the effects of the COVID-19 social distancing on function, health and well-being of patients with Parkinson's disease or post-stroke, and test the association between the patient activation level and these effects.An anonymous survey was distributed through social media and patient associations.Community-living patients with Parkinson's disease or post-stroke were invited to answer the survey.
Description: The PAM is a self-reported validated, licensed tool to measure a patient's knowledge, skills and confidence for self-management. The overall score captures the extent to which people feel engaged and confident in taking care of their health condition. It consists of 13 statements rated on a Likert scale according to agreement. Scores are divided into 4 levels, where 1 represents patients who tend to be passive and feel overwhelmed managing their own health, and 4 represents patients who have effectively adopted self-management behaviors. We used a validated licensed Hebrew and version of the PAM supplied by Insignia Health (https://www.insigniahealth.com/products/pam-survey), which holds the copyright to the questionnaire.
Measure: Patient Activation Measure (PAM®) Time: 1 hourDescription: participants were asked to answer 27 multiple-choice questions regarding status and change in status of mobility, mood (depression, anxiety), tiredness, social support, body weight, physical activity, rehabilitative treatments and disease symptoms
Measure: Answers to multiple-choice questions Time: 1 hourThe COVID-19 pandemic has had dramatic effects on health systems and on non-COVID health care. Using French inpatient claims data and retrospectively collected clinical data, the investigators will assess the changes in hospital admissions for acute cardiovascular and neurovascular conditions in France during and after the national lockdown.
Description: Daily number of admissions for acute cardio- and neurivascular conditions in France.
Measure: Daily number of admissions for acute cardio- and neurivascular conditions in France. Time: 1 dayDescription: Specific mortality rate.
Measure: Specific mortality rate. Time: 1 daySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has begun, first in Wuhan, China, and then became a pandemic. The first SARS-CoV-2 case in Turkey was reported on March 11, 2020. People older than 65 years old became subject to lock down measures beginning on March 21, while people younger than 20 years old became subject to lock down measures beginning on April 03. A total lock down has been implemented a few times lasting between 3 to 4 days, especially at weekends. Several studies show that mental health problems could occur in public during the SARS-CoV-2 pandemic. Depression and anxiety are a commonly known mental health issue in post-stroke patients. This patient population, who usually have to spend most of their time at home, remained completely at home and socially isolated due to the precautions required by the pandemic. Based on the above research evidence; depression, anxiety and phobia of SARS-CoV-2 may increase in the post stroke patients due to being in risk group and effects of measures taken against SARS-CoV-2 pandemic. Therefore, we aimed to assess the depression, anxiety and SARS-CoV-2 phobia in post stroke patients during SARS-CoV-2 outbreak, and to explore the potential influence factors.
Description: The Hospital Anxiety and Depression Scale evaluation includes a total of 14 questions (score range 0-3), which are scored to separately estimate anxiety and depressive status (7 questions each). The individual score for the anxiety and depression subscales may vary from 0 to 21. The aim of this scoring system is not to make an objective diagnosis, but to determine the current presence and tendency to anxiety or depression at the time of diagnosis. A HADS score of 8 to 10 is broadly accepted as indicating mild symptoms, a score between 11-16 suggests moderate anxiety or depression, and a score of 16 or more indicates severe anxiety or depressive symptoms
Measure: Hospital Anxiety and Depression Scale Time: 3 monthsDescription: The Covid 19 Phobia Scale is a self-report instrument with a five-point Likert-type scale to assess the levels of SARS-CoV-2 phobia. All items are rated on a 5-point scale from "strongly disagree (1)" to "strongly agree (5)." The scores on the scale can range between 20 and 100 and a higher score indicates a greater phobia in the respected subscales and total scale. In the present study total scale scores ranged from 20 to 100. The scale examines four main factors: psychological, psycho-somatic, economic and social
Measure: Covid 19 Phobia Scale Time: 3 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports